Why this small-cap stock could be the UK’s most exciting investment opportunity right now

Edward Sheldon identifies a fast-growing small-cap biotech stock that he believes has considerable potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m looking at two contrasting small-cap stocks. One is a stock that I would steer well clear of, while the other appears to be a genuinely exciting investment opportunity, in my opinion.

Trending lower

Once a bulletin board favourite, Nanoco (LSE: NANO) has been a disappointment in recent years. The £60m market cap company manufactures quantum dots – miniscule fluorescent semiconductor nanoparticles that emit different colours, and are used in applications such as lighting, bio-imaging and solar energy. While the technology sounds interesting, Nanoco has failed to deliver for shareholders.

The company’s financials don’t make for great reading. For example, last year revenue fell to £0.47m from £2.03m the year before, and the group recorded a net loss of £10.6m. While revenue is expected to climb to £1.55m for the year ended 31 July, another hefty net loss of £9.8m is anticipated.

Furthermore, the group has struggled to generate adequate cash flow, and was forced to raise £8.6m last week at a significant discount to the share price at the time. That’s clearly a disappointment for existing investors, as the fundraising will dilute their shareholdings significantly. 

Nanoco’s share price has been locked in a downtrend for the past four years now, declining from around 180p to 26p today. With that in mind, I’ll be steering well clear of the company.

Surging higher

However, as a contrast, one small-cap company that looks very interesting, in my opinion, is £140m market cap Bioventix (LSE: BVXP). Trading at just under 1,400p at the start of the year, the shares now change hands for 2,900p, a year-to-date gain of over 100%. Furthermore, since moving to AIM in 2014, the stock has risen by an amazing 400%.

So what’s all the hype about and more importantly, can the momentum continue?

Bioventix specialises in the development and commercial supply of sheep antibodies for use in immunodiagnostics. Antibodies are proteins that are produced by the immune system to help stop viruses, infections, bacteria and disease harming the body, and Bioventix claim that its sheep-derived antibodies are more effective than traditional rodent-based varieties. The firm earns revenue by licensing its products to other companies that use them for clinical diagnostic applications such as blood testing.

A glance at Bioventix’s financials reveals a spectacular set of numbers. Over the last three years, revenue has risen from £2.7m to £5.5m, and earnings per share have surged from 30p to 68p, a compound annual growth rate (CAGR) of 31%. Equally impressive have been the company’s operating margins and return on equity, which last year, were 76% and 42% respectively. Dividend growth of 190% over the last three years has also been recorded. 

Interim results in March saw sales rise 32% to £3.1m, and profit before tax increase 49% to £2.5m. Then, in early September, the group upgraded its full-year profit guidance, stating: “Both revenues and profits before tax are expected to be ahead of market expectations for the year ended 30 June 2017.

So it’s pretty clear, to my mind, that Bioventix has strong momentum at present. Is it too late to jump on board? On consensus FY2017 earnings estimates of 89.3p, it currently trades on a P/E ratio of 32.5. While that valuation is no doubt high, it doesn’t look entirely unreasonable in my view, given the company’s track record and growth prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much would I need to invest in income shares to earn £300 a month?

What kind of lump sum would be required to earn £300 a month by taking advantage of some of the…

Read more »

Investing For Beginners

Up 31% in a month, could this FTSE 250 stock be getting bought out?

Jon Smith takes a look at speculation that's pushing the share price of a FTSE 250 share higher and considers…

Read more »

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »